Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Supplemental Cash Flow Information

Supplemental Cash Flow Information

12 Months Ended

Dec. 31, 2013

Supplemental Cash Flow Information

11. SUPPLEMENTAL CASH FLOW INFORMATION:

	For the year ended December 31, 2013	For the year ended December 31, 2012	For the period from March 29, 2011 (date of inception) through December 31, 2013
Cash paid for interest	$ 107,913	$ 178,316	$ 448,229
Cash paid for income taxes	$ 100	$ 100	$ 200
Series C Dividend payable in accrued expenses	$ 22,668	$ 49,172	$ 22,668
Series D Dividend payable in accrued expenses	$ 44,018	$ --	$ 44,018

Non-Cash investing and financing transactions
Repayment of senior secured notes payable with issuance of Series D preferred shares	$ 749,982	$ --	$ 749,982
Financing the purchase of equipment under a 5 year loan agreement	$ 83,507	$ --	$ 83,507
Beneficial conversion feature on warrants issued in conjunction with Series D preferred shares	$ 176,729	$ --	$ 176,729